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Abstract
Introduction: To determine whether IL4R single-nucleotide polymorphisms (SNPs) rs1805010 (I50V) and rs1801275 
(Q551R), which have been associated with disease severity in rheumatoid arthritis (RA) patients of European ancestry, 
relate to the presence of rheumatoid nodules and radiographic erosions in African Americans.
Methods: Two IL4R SNPs, rs1805010 and rs1801275, were genotyped in 749 patients from the Consortium for 
Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR) registries. End points were 
rheumatoid nodules defined as present either by physical examination or by chest radiography and radiographic 
erosions (radiographs of hands/wrists and feet were scored using the modified Sharp/van der Heijde system). Statistical 
analyses were performed by using logistic regression modeling adjusted for confounding factors.
Results: Of the 749 patients with RA, 156 (20.8%) had rheumatoid nodules, with a mean age of 47.0 years, 84.6% female 
gender, and median disease duration of 1.9 years. Of the 461 patients with available radiographic data, 185 (40.1%) had 
erosions (score >0); their mean age was 46.7 years; 83.3% were women; and median disease duration was 1.5 years. 
Patients positive for HLA-DRB1 shared epitope (SE) and autoantibodies (rheumatoid factor (RF) or anti-cyclic 
citrullinated peptide (CCP)) had a higher risk of developing rheumatoid nodules in the presence of the AA and AG 
alleles of rs1801275 (odds ratio (OR)adj = 8.08 (95% confidence interval (CI): 1.60-40.89), P = 0.01 and ORadj = 2.97 (95% CI, 
1.08 to 8.17), P = 0.04, respectively). Likewise, patients positive for the HLA-DRB1 SE and RF alone had a higher risk of 
developing rheumatoid nodules in presence of the AA and AG alleles of rs1801275 (ORadj = 8.45 (95% CI, 1.57 to 45.44), 
P = 0.01, and ORadj = 3.57 (95% CI, 1.18 to 10.76), P = 0.02, respectively) and in the presence of AA allele of rs1805010 
(ORadj = 4.52 (95% CI, 1.20 to 17.03), P = 0.03). No significant association was found between IL4R and radiographic 
erosions or disease susceptibility, although our statistical power was limited by relatively small numbers of cases and 
controls.
Conclusions: We found that IL4R SNPs, rs1801275 and rs1805010, are associated with rheumatoid nodules in 
autoantibody-positive African-American RA patients with at least one HLA-DRB1 allele encoding the SE. These findings 
highlight the need for analysis of genetic factors associated with clinical RA phenotypes in different racial/ethnic 
populations.
Introduction
Rheumatoid arthritis (RA) is a disease of unknown etiology
with a prevalence of 1% in populations of European ances-
try [1]; it seems to be less prevalent in patients of African
ancestry than in persons of European heritage [2]. Predic-
tors of disease severity include environmental factors
(socioeconomic status and smoking history), clinical fac-
tors (the number of swollen and tender joints and the pres-
ence of extraarticular manifestations and erosions at
baseline) [3], laboratory data (presence of rheumatoid fac-
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(anti-CCP) [4], higher sedimentation rate (ESR) or C-reac-
tive protein (CRP) levels), and other variables (educational
level, score in the Health Assessment Questionnaire
(HAQ)). In addition, the HLA-DRB1 shared epitope (SE)
has been associated with both disease severity and suscepti-
bility [5], and other loci have been associated also with RA
in multiple genome-wide association studies (GWASs)
[6,7]. Some of these studies have used radiographic param-
eters to assess disease progression [8,9].
It has been suggested that interleukin-4 (IL-4) and its
receptor, encoded by IL4R, could play a role in the patho-
genesis of RA [8,10] because diminished production of IL-
4 may contribute to the TH1-mediated autoimmune inflam-
matory response characteristic of this disease [11,12]. Fur-
thermore, an imbalance in the TH1-to-TH2 ratio in the
adaptive immune response occurs in a variety of immune
disorders, including RA. Seven single-nucleotide polymor-
phisms (SNPs) have been identified in the coding region of
IL4R [13-15]. Two of these SNPs, rs1805010 (I50V) and
rs1801275 (Q551R), are nonsynonymous [16] and are
thought to be important in asthma and atopic diseases, as
IL-4 plays a major role in IgE production [15,17].
The role of rs1805010 and rs1801275 in RA is controver-
sial. Prot et al. [8] reported an association of these genetic
variants with the rapid development of erosions and a
diminished responsiveness to IL-4 by CD4+ T cells in Ger-
man RA patients, whereas Marinou et al. [18] failed to sup-
port such associations in an English population.
Because minority groups are often underrepresented in
observational studies and randomized clinical trials [19,20],
we evaluated in African-Americans patient with RA
whether these ILR4 SNPs are associated with rheumatoid
nodules and erosions, two clinical manifestations associ-
ated with disease severity. This study may improve our
understanding of the disease course in these patients and
possibly help to identify the presence of ethnic-specific risk
factors [19-22].
Materials and methods
Study population
The Consortium for the Longitudinal Evaluation of African
Americans with Early Rheumatoid Arthritis (CLEAR) reg-
istry is a National Institute of Arthritis and Musculoskeletal
and Skin Diseases-funded program enrolling self-identified
African Americans with RA, as defined by the revised
American College of Rheumatology (ACR) classification
criteria [23]. Patients with disease duration of <2 years
were enrolled in CLEAR I, a longitudinal cohort, from 2000
to 2005. Patients with any disease duration were enrolled in
CLEAR II, a cross-sectional arm of the registry, beginning
in 2006. Enrollment in CLEAR II is ongoing. Comprehen-
sive demographic, clinical, and radiographic data were
obtained from CLEAR I participants at the baseline visit and
at 36 and 60 months from disease onset, and at one time
point in CLEAR II participants. Data on current and previ-
ous drug treatments, including disease-modifying antirheu-
matic drugs (DMARDs), biologic agents, and
glucocorticoids were collected. Participants were recruited,
informed consents were obtained from study participants by
study coordinators, and studies were conducted under
approval by the Institutional Review Boards of the partici-
pating institutions: The University of Alabama at Birming-
ham (UAB) (Coordinating Center), Emory University
(Atlanta, GA); The Medical University of South Carolina
(Charleston), The University of North Carolina at Chapel
Hill, and Washington University (St. Louis, MO). A group
of 282 healthy African Americans matched for age and gen-
der without RA, recruited as part of the CLEAR Registry,
were used as a control group.
Variables ascertained included age, ethnicity, education,
poverty (as defined by the United States Federal Govern-
ment and adjusted for the number of subjects in the house-
hold [24]), history of RA in a first-degree relative, smoking
history (self-reported ever or never), disease duration, the
ACR core set of variables (number of swollen joints, num-
ber of painful joints, pain scale (assessed with a 0 to 10
Visual Analog Scale)) [25], functional status assessed with
the Health Assessment Questionnaire [26], and presence of
extraarticular manifestation (pulmonary fibrosis, Sjögren
syndrome, pericarditis, vasculitis, skin ulcers, or scleritis).
The following laboratory variables were recorded at enroll-
ment: serum CRP measured with a high-sensitivity immu-
nometric assay (hsCRP; Immulite 2000 Diagnostic
Products, Los Angeles, CA), anti-CCP antibody (IgG)
detected with a second-generation enzyme-linked immuno-
sorbent assay (ELISA; Diastat, Axis-Shield Diagnostics,
Dundee, Scotland), and rheumatoid factor measured with
ELISA (INOVA Diagnostics, San Diego, CA, USA) [27].
Rheumatoid nodules and radiographic erosions
The presence of rheumatoid nodules was defined by history
and physical examination at enrollment. Participants who
reported a history of rheumatoid nodules on chest imaging
were also considered to have rheumatoid nodules. All RA
participants underwent radiographic evaluations of their
hands/wrists (posteroanterior views) and feet (anteroposte-
rior views). Study radiographs were read by an experienced
reader blinded to all clinical and demographic data, who
scored the radiograph for erosions and joint-space narrow-
ing (JSN) by using the van der Heijde modified Sharp
method [28,29]. The presence of erosions and JSN for each
patient was defined by scores greater than zero; only the
baseline evaluations were included in these analyses
because of the limited number of follow-up radiographs in
this ongoing study [30].
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Genotypes for rs1805010 and rs1801275 were determined
by TaqMan (Applied Biosystems (ABI), Foster City, CA)
on an ABI 7900 HT Sequence Detection System. HLA-
DRB1 shared epitope (SE) status was determined as previ-
ously described [31].
Statistical analyses
The analyses were performed by using SAS 9.1 (Cary, NC).
Separate comparisons between socioeconomic, demo-
graphic, clinical, and laboratory characteristics as a func-
tion of the presence of rheumatoid nodules and erosions
were performed. Categoric variables were compared by
using the Pearson χ2 test, whereas continuous variables
were compared with independent t tests and the nonpara-
metric Wilcoxon rank-sum test, where appropriate. A two-
tailed P value of <0.05 was chosen as the statistically sig-
nificant level. We analyzed potential associations between
the IL4R SNPs and the presence of rheumatoid nodules and
radiographic erosions, by using univariate and multivariate
analyses. Logistic regression models were used to analyze
the odds of having rheumatoid nodules and erosions as a
function of the presence of IL4R SNPs, adjusted by nodules
or erosions (according to the outcome analyzed), age at RA
onset, gender, disease duration (≥2 years versus <2 years),
smoking, and methotrexate use. The patients were stratified
by the presence of autoantibodies (anti-CCP or RF positive,
as one or separate), and HLA-DRB1 SE. Hardy-Weinberg
equilibrium for the distribution of genotypes was examined
with Fisher's Exact test.
Results
Patient characteristics
In total, 749 African-American RA patients from CLEAR I
and II were analyzed. The mean age at RA onset was 47.0
years, and 84.6% of patients were women. Median disease
duration was 1.9 years; 86% of the patients had either anti-
CCP antibodies or RF.
Of the 749 RA participants, 156 (20.8%) had rheumatoid
nodules; these patients had more comparable ages at dis-
ease onset than did those without nodules but were more
likely to have longer disease duration, a smoking history,
higher HAQ scores, increased presence of joint-space nar-
rowing and of autoantibodies, and higher levels of CRP
(Table 1).
Radiographic scores at enrollment were available in 461
CLEAR I and CLEAR II RA participants. Of these 461
patients, 185 (40.1%) patients had at least one radiographic
erosion. RA participants with erosions were younger at RA
onset, had longer disease duration, were more likely to have
joint-space narrowing and autoantibodies, and to have been
treated with methotrexate (Table 1).
The distribution of patients with other extraarticular man-
ifestations was as follows: 16 (2.2%) pulmonary fibrosis,
21 (2.9%) Sjögren syndrome, six (0.8%) pericarditis, three
(0.4%) vasculitis, 11 (1.5%) skin ulcers, and 16 (2.2%)
scleritis.
Lack of association with IL4R genotype and disease 
susceptibility
Each SNP was in Hardy-Weinberg equilibrium, and the fre-
quencies were similar to those reported in other studies for
rs1805010 but different for rs1801275 [8,32,33]. No signif-
icant differences were found in the genotype and allele fre-
quencies between controls and RA patients. For rs1805010,
frequencies were 23.7% and 26.5% for homozygous AA
and GG genotypes, respectively, and 49.8% for the
heterozygous AG genotype. Likewise, rs1801275 frequen-
cies were 9.9% and 46.6% for homozygous AA and GG
genotypes, respectively, and 43.5% for the heterozygous
AG genotype.
Association of IL4R SNPs with rheumatoid nodules
No significant association between the rs1801275 and
rs1805010 alleles and rheumatoid nodules were found in
the unadjusted and adjusted analyses (data not shown).
After stratification for the presence of HLA-DRB1 SE and
autoantibody status (RF or anti-CCP) in multivariable mod-
els, the rs1801275 AA genotype (ORadj = 8.08 (95% CI,
1.60 to 40.89); P = 0.01] and AG genotype (ORadj = 2.97
(95% CI, 1.08 to 8.17), P = 0.04)] were found to be associ-
ated with rheumatoid nodules (Table 2). Similarly, stratify-
ing separately by the presence of HLA-DRB1 SE and anti-
CCP antibodies, the AA and AG genotypes of rs1801275
were associated with rheumatoid nodules (ORadj = 8.12
(95% CI, 1.59 to 41.44), P = 0.01; and ORadj = 2.96 (95%
CI, 1.15 to 7.62), P = 0.02; respectively) in the multivari-
able model (data not shown). Likewise, stratifying sepa-
rately by the presence of HLA-DRB1 SE and RF, the
rs1801275 AA and AG genotypes (ORadj = 8.45 (95% CI,
1.57 to 45.44), P = 0.01; and ORadj = 3.57 (95% CI, 1.18 to
10.76), P = 0.02, respectively] and the rs1805010 AA geno-
type (ORadj = 4.52 (95% CI, 1.20 to 17.03), P = 0.03) were
associated with rheumatoid nodules (data not shown).
Lack of association of IL4R SNPs with radiographic erosions
No significant association between the presence of radio-
graphic erosions and the SNPs examined was found in any
of the unadjusted and adjusted analyses performed. Specifi-
cally, statistical significance was not reached after stratifi-
cation by the presence or absence of HLA-DRB1 SE and
anti-CCP or RF status (alone or combination). These data
are shown in Table 3.
Discussion
This is the first study conducted in African-American RA
patients to determine the relation between the occurrence of
rheumatoid nodules and erosions and the presence of the
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found that the rs1801275 AA and AG genotypes and the
rs1805010 AA genotype were associated with rheumatoid
nodules in African-American RA patients who are HLA-
DRB1 SE positive and autoantibody positive.
The minor allele frequency of rs1805010 in African
Americans patients with RA was found to be of similar fre-
quency to that in the English and German studies [8,18]; in
contrast, the minor allele frequency of rs1801275 was
found to be different from that in these two European popu-
lations. These findings must be considered to understand
the disease phenotypes in patients of different ethnicities.
As expected, rheumatoid nodules were associated with
disease duration, smoking, HAQ score, JSN, RF, anti-CCP
antibodies, elevated CRP levels, and methotrexate use.
However, HLA-DRB1 SE status alone does not appear to
increase significantly the risk of rheumatoid nodules among
African Americans. Several studies conducted in patients of
European descent found no association between the SE and
rheumatoid nodules [34-37], whereas others found such an
association [38,39]. Thus, the genetic predisposition to the
development of rheumatoid nodules is complex and
involves more than the presence of the SE and its interac-
tion with environmental factors, such as smoking [40,41] or
medications [42]. However, the SE has a smaller absolute
effect in African Americans than in individuals of European
descent [20,31].
The presence of radiographic erosions was associated
with age, disease duration, the presence of JSN, RF, anti-
CCP antibodies, and methotrexate use, but it was not asso-
ciated with HLA-DRB1 SE, CRP levels, HAQ score, or
smoking. After stratification by the presence of the SE and
RF or anti-CCP antibodies (alone or in combination), no
association between erosions and rs1805010 or rs1801275
Table 1: Baseline sociodemographic, clinical, and laboratory characteristics of RA patients in the CLEAR registries as a 
function of the presence of erosions or rheumatoid nodules
Radiographic erosions Rheumatoid nodules
Variable Present n = 185 Absent n = 276 Pf Present n = 156 Absent n = 593 Pf
Age at RA onset, 
years, mean (SD)
45.3 (14.5) 48.3 (12.6) 0.02 45.6 (12.6) 47.8 (13.6) 0.06
Disease duration,a 
years, median 
(IQRb)
3.8 (1.2-15.5) 1.2 (6.0-2.0) <0.0001 7.5 (1.3-15.6) 1.8 (0.8-8.0) <0.001
Smoking, ever,c n 
(%)
98 (54.4) 139 (51.9) 0.59 95 (61.7) 295 (50.3) 0.01
HAQd score, 
median (IQR)
2.0 (1.3-2.4) 1.8 (0.9-2.4) 0.27 2.1 (1.3-2.6) 1.8 (1.0-2.4) 0.01
Joint-space 
narrowing at 
baseline, present 
(score >0), n (%)
132 (71.4) 34 (12.3) <0.001 48 (53.3) 116 (31.9) <0.001
Rheumatoid factor 
positive, n (%)
145 (87.3) 182 (74.3) 0.001 127 (90.7) 418 (77.1) <0.001
Anti-CCP antibody 
positive, n (%)
148 (81.3) 159 (59.3) <0.001 127 (84.1) 375 (65.2) <0.001
Abnormal C-
reactive protein 
(>5 mg/L), n (%)
94 (51.9) 126 (46.5) 0.26 77 (58.8) 238 (44.7) <0.004
HLA-DRB1 present,e 
n (%)
78 (42.9) 113 (41.1) 0.71 64 (43.2) 234 (39.9) 0.45
Methotrexate use, 
ever,c n (%)
149 (82.3) 175 (64.6) <0.001 127 (81.9) 423 (72.2) 0.01
aDisease duration at enrollment: duration between self-reported onset of symptoms and date of enrollment; bIQR interquartile range (25th 
and 75th); ccurrent or past; dHeath Assessment Questionnaire; eHLADRB1 was made to determine SE positive; fTwo-tailed P value by 
independent-sample t test, Wilcoxon rank-sum test, or χ2 test for proportions, as appropriate and wherever applicable, missing data were 
excluded from the denominator for calculating percentage and P value.
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[18] in a cross-sectional study of 965 white RA patients and
988 healthy controls; however, our data do not corroborate
the report by Prots et al. [8] of a higher risk of developing
early erosions, as noted in their longitudinal German cohort
of 302 RA patients. Perhaps this effect was not observed
because of the different racial/ethnic composition of the
patients studied; in African Americans, these polymor-
phisms could be modulators of other phenotypes.
Because RF and anti-CCP antibodies have similar sensi-
tivities, but anti-CCP antibodies have a higher specificity
[27], we decided to stratify by these autoantibodies when
assessing the relation with rheumatoid nodules and radio-
graphic erosions. We found no association between HLA-
DRB1 SE/anti-CCP positivity with rheumatoid nodules or
erosions, but a new association was found between
rs1805010 (AA genotype) and HLA-DRB1 SE/RF positiv-
ity. Thus, HLA-DRB1 SE/RF-positive patients with the AA
genotype of rs1805010 and the AA or AG genotype of
rs1801275 have a higher risk of rheumatoid nodules than do
those patients without this feature. The higher sensitivity
and specificity of RF for the presence of extraarticular man-
ifestations as compared with anti-CCP antibodies, as
reported in other studies [4,43,44], is a probable explana-
tion for our findings.
There are several limitations to our study. Complete
radiographic baseline data and genotyping are not available
because the study is ongoing. Only 25% of CLEAR I RA
participants had erosions at baseline, given the enrollment
criterion of disease onset <2 years. In addition to restricting
the analysis to a small number of subjects, the inclusion of
early RA patients might miss a subset of patients who
would go on to develop extraarticular manifestations with
longer disease duration. Furthermore, we only analyzed two
SNPs of ILR4, and our results could be influenced by the
interactions of other SNPs within these genes or other genes
whose proteins are associated with TH1-to-TH2 balance.
Conclusions
In conclusion, we found that both rs1801275 and
rs1805010 are associated with rheumatoid nodules in Afri-
can-American RA patients with the HLA-DRB1 SE and
autoantibodies. These findings may allow future stratifica-
tion of the risk of extraarticular manifestations in RA.
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Table 3: Association of rs1805010 and rs1801275 with radiographic erosions after stratification by the presence of HLA-
DRB1 SE and autoantibodies in African Americans with RA
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Gender + Disease duration (≥2 years versus <2 years) + rheumatoid nodules + smoking (ever versus never) + methotrexate (ever versus 
never).
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